BNP Paribas Asset Management
APGE

BNP Paribas Asset Management’s Apogee Therapeutics APGE Stock Holding History

BNP Paribas Asset Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.3K Sell
567
-53,870
-99% -$4.85M ﹤0.01% 1631
2026
Q1 		$4.58M Buy
54,437
+14,591
+37% +$1.06M 0.01% 881
2025
Q4 		$3.01M Buy
39,846
+39,644
+19,626% +$2.5M ﹤0.01% 970
2025
Q3 		$8K Hold
202
– – ﹤0.01% 1682
2025
Q2 		$9K Buy
+202
New +$7.68K ﹤0.01% 1797

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BNP Paribas Asset Management's APGE Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Apogee Therapeutics (APGE) stake by 99% in Q2 2026, selling an estimated $4.85M and leaving 567 shares worth $75.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1631.

BNP Paribas Asset Management first reported a position in APGE in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.58M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • BNP Paribas Asset Management held 567 shares of Apogee Therapeutics worth $75.3K as of Q2 2026.
  • BNP Paribas Asset Management sold 53,870 Apogee Therapeutics shares in Q2 2026, an estimated $4.85M.
  • Apogee Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1631 holding.
  • BNP Paribas Asset Management first reported a position in Apogee Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Asset Management's Apogee Therapeutics position peaked at $4.58M in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.